PURPOSE:Late gastrointestinal (GI) and genitourinary (GU) morbidity from external beam irradiation used to treat adenocarcinoma of the prostate continue to be a concern of physicians and patients alike. In addition, for locally advanced/high-risk cancer, the appropriate use of hormonal manipulation in addition to radiation therapy (RT) may increase toxicity. We analyzed three large Radiation Therapy Oncology Group (RTOG) studies (85-31, 86-10, and 92-02) to try to address these issues. METHODS AND MATERIALS: A total of 2,922 patients were accrued with a median follow-up of 10.3 years for surviving patients. The RTOG scoring scheme was used to assess GI, GU, and other toxicities. Toxicity reported was Grade 3 or higher late toxicity. Patient toxicity level was assessed by study and by treatment type combining RT only vs. RT + short-course hormone therapy (STH) vs. RT + long-term hormone therapy (LTH). RESULTS: Multivariate analysis reveals that age >70 was statistically significantly associated with a decrease in late any Grade 3+ toxicity (hazard ratio [HR] = 0.78, p = 0.0476) adjusted for treatment type. Comparing treatment type, patients treated with RT+STH had a statistically significant lower probability of Grade 3+ GI, GU, and other toxicity compared with RT alone (p = .00006; p = 0.0037; p = 0.0127, respectively). Patients treated with RT+LTH had a statistically significant lower probability of Grade 3+ GU toxicity compared with RT alone (p = 0.023). CONCLUSIONS: These data show that external beam radiation therapy remains a safe option for locally advanced/high-risk prostate cancer, and the use of hormonal manipulation does appear to be protective for GU and GI toxicity depending upon length of treatment.
RCT Entities:
PURPOSE: Late gastrointestinal (GI) and genitourinary (GU) morbidity from external beam irradiation used to treat adenocarcinoma of the prostate continue to be a concern of physicians and patients alike. In addition, for locally advanced/high-risk cancer, the appropriate use of hormonal manipulation in addition to radiation therapy (RT) may increase toxicity. We analyzed three large Radiation Therapy Oncology Group (RTOG) studies (85-31, 86-10, and 92-02) to try to address these issues. METHODS AND MATERIALS: A total of 2,922 patients were accrued with a median follow-up of 10.3 years for surviving patients. The RTOG scoring scheme was used to assess GI, GU, and other toxicities. Toxicity reported was Grade 3 or higher late toxicity. Patienttoxicity level was assessed by study and by treatment type combining RT only vs. RT + short-course hormone therapy (STH) vs. RT + long-term hormone therapy (LTH). RESULTS: Multivariate analysis reveals that age >70 was statistically significantly associated with a decrease in late any Grade 3+ toxicity (hazard ratio [HR] = 0.78, p = 0.0476) adjusted for treatment type. Comparing treatment type, patients treated with RT+STH had a statistically significant lower probability of Grade 3+ GI, GU, and other toxicity compared with RT alone (p = .00006; p = 0.0037; p = 0.0127, respectively). Patients treated with RT+LTH had a statistically significant lower probability of Grade 3+ GU toxicity compared with RT alone (p = 0.023). CONCLUSIONS: These data show that external beam radiation therapy remains a safe option for locally advanced/high-risk prostate cancer, and the use of hormonal manipulation does appear to be protective for GU and GI toxicity depending upon length of treatment.
Authors: C A Lawton; M Won; M V Pilepich; S O Asbell; W U Shipley; G E Hanks; J D Cox; C A Perez; W T Sause; S R Doggett Journal: Int J Radiat Oncol Biol Phys Date: 1991-09 Impact factor: 7.038
Authors: Miljenko V Pilepich; Kathryn Winter; Colleen A Lawton; Robert E Krisch; Harvey B Wolkov; Benjamin Movsas; Eugen B Hug; Sucha O Asbell; David Grignon Journal: Int J Radiat Oncol Biol Phys Date: 2005-04-01 Impact factor: 7.038
Authors: M V Pilepich; K Winter; M J John; J B Mesic; W Sause; P Rubin; C Lawton; M Machtay; D Grignon Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Eric M Horwitz; Kyounghwa Bae; Gerald E Hanks; Arthur Porter; David J Grignon; Harmar D Brereton; Varagur Venkatesan; Colleen A Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Mitchell Liu; Tom Pickles; Alexander Agranovich; Eric Berthelet; Graeme Duncan; Mira Keyes; Winkle Kwan; Michael McKenzie; James Morris; Howard Pai; Scott Tyldesley; Jonn Wu Journal: Int J Radiat Oncol Biol Phys Date: 2004-01-01 Impact factor: 7.038
Authors: Gerald E Hanks; Thomas F Pajak; Arthur Porter; David Grignon; Harmart Brereton; Varagur Venkatesan; Eric M Horwitz; Colleen Lawton; Seth A Rosenthal; Howard M Sandler; William U Shipley Journal: J Clin Oncol Date: 2003-11-01 Impact factor: 44.544
Authors: G Sanguineti; S Agostinelli; F Foppiano; P Franzone; S Garelli; M Marcenaro; M Orsatti; V Vitale Journal: Br J Cancer Date: 2002-06-17 Impact factor: 7.640
Authors: M Kamrava; A H Kesarwala; R A Madan; E Lita; A Kaushal; K-Y Tsang; D J Poole; S M Steinberg; T Ferrara; W Dahut; J Schlom; J L Gulley Journal: Prostate Cancer Prostatic Dis Date: 2012-03-06 Impact factor: 5.554
Authors: A Zapatero; M Roch; D Büchser; P Castro; L Fernández-Banda; G Pozo; O Liñán; C Martin de Vidales; A Cruz-Conde; F García-Vicente Journal: Clin Transl Oncol Date: 2017-04-03 Impact factor: 3.405